Gilead Sciences (NQ:GILD)

Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade ↗

October 29, 2026

Via Investor's Business Daily

Gilead Sciences Announces Third Quarter 2026 Financial Results

October 29, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...

Gilead Sciences earnings: what to look for from GILD

October 27, 2026

Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support ↗

October 05, 2026

Via Chartmill

Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup ↗

October 02, 2026

Via Chartmill

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? ↗

October 27, 2026

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? ↗

Topics ETFs

October 25, 2026

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Both of these biotech stocks could be appealing to income investors.

Topics ETFs

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? ↗

October 25, 2026

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗

October 23, 2026

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Topics ETFs

October 22, 2026

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

October 22, 2026

Both of these ETFs look the part, but only one is truly the better buy for investors.

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? ↗

October 22, 2026

Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and...

Topics ETFs

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day ↗

October 21, 2026

Via MarketBeat

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

October 19, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

1 Unprofitable Stock with Exciting Potential and 2 We Find Risky

October 19, 2026

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? ↗

October 18, 2026

The company's recent momentum continues unabated.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

3 Inflated Stocks Walking a Fine Line

October 16, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

October 11, 2026

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Topics ETFs

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH ↗

October 10, 2026

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma ↗

Topics ETFs

October 10, 2026

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...

Topics ETFs

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated...

Topics Artificial Intelligence

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets ↗

October 05, 2026

Via MarketBeat

Topics Artificial Intelligence

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB ↗

October 05, 2026

VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Topics ETFs

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.

Topics ETFs

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK ↗

September 25, 2026